Recent

% | $
Quotes you view appear here for quick access.

Celldex Therapeutics, Inc. Message Board

  • unagogirl unagogirl Nov 17, 2012 11:58 AM Flag

    Press Release

    Celldex Therapeutics (NASDAQ: CLDX) reported in a release on Thursday the presentation of three-year survival data from the Phase 2 rindopepimut clinical program in EGFRvIII-positive glioblastoma, a more aggressive form of glioblastoma typically associated with reduced long-term survival when compared to the entire glioblastoma population. Further, across three Phase 2 studies of rindopepimut, the survival data remains consistent and implies a substantial and continuing survival benefit, when compared to independent control data sets at the median and also at three years.

 
CLDX
3.78-0.12(-3.08%)Aug 23 4:00 PMEDT